1. Home
  2. NMIH vs LQDA Comparison

NMIH vs LQDA Comparison

Compare NMIH & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NMI Holdings Inc.

NMIH

NMI Holdings Inc.

HOLD

Current Price

$37.26

Market Cap

3.1B

Sector

Finance

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$36.45

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMIH
LQDA
Founded
2011
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.1B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
NMIH
LQDA
Price
$37.26
$36.45
Analyst Decision
Buy
Strong Buy
Analyst Count
4
11
Target Price
$43.00
$40.36
AVG Volume (30 Days)
343.9K
1.5M
Earning Date
04-28-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
11.06
51.81
EPS
4.92
N/A
Revenue
$706,440,000.00
$158,320,000.00
Revenue This Year
N/A
$208.46
Revenue Next Year
$4.34
$27.44
P/E Ratio
$7.56
N/A
Revenue Growth
8.52
1031.18
52 Week Low
$32.71
$11.26
52 Week High
$43.20
$46.67

Technical Indicators

Market Signals
Indicator
NMIH
LQDA
Relative Strength Index (RSI) 38.20 51.94
Support Level $36.78 $30.48
Resistance Level $37.66 $39.19
Average True Range (ATR) 0.74 2.15
MACD -0.16 0.44
Stochastic Oscillator 25.54 72.92

Price Performance

Historical Comparison
NMIH
LQDA

About NMIH NMI Holdings Inc.

NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: